bezafibrate has been researched along with Obesity in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 13 (59.09) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Honda, A; Ishii, I | 1 |
| Aguila, MB; Correia, AL; dos Anjos, TL; Faria, Tda S; Mandarim-de-Lacerda, CA | 1 |
| Aguila, MB; Bargut, TC; de Carvalho, SN; Magliano, DC; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Aoki, K; Goto, T; Iijima, Y; Kawada, T; Kim, YI; Shibata, D; Suda, K; Suzuki, H; Takahashi, H; Takahashi, N; Takino, A; Yamazaki, Y | 1 |
| Aichler, M; Brachthäuser, L; Feuchtinger, A; Franko, A; Fuchs, H; Häring, HU; Hrabě de Angelis, M; Kovarova, M; Neff, F; Neschen, S; Peter, A; Rathkolb, B; Rozman, J; Wolf, E | 1 |
| Barbosa Aguila, M; de Souza Mendonca, L; Evangelista Carneiro, R; Fernandes-Santos, C; Mandarim-de-Lacerda, CA | 1 |
| Aburada, M; Hokao, R; Iizuka, S; Makihara, H; Sasaki, Y; Shimada, T; Suzuki, W; Teraoka, R; Tsuneyama, K | 1 |
| Gao, Z; Jia, W; Li, H; Xu, A; Ye, J; Ye, X; Zhang, J | 1 |
| Mori, Y | 1 |
| Bamberg, K; Camejo, G; Dahllöf, B; Kjellstedt, A; Ljung, B; Oakes, ND; Ostling, J; Svensson, L | 1 |
| Nakagawa, M; Onishi, T; Saibara, T; Saika, K; Shizuta, Y; Sugiura, T; Takeda, K; Toda, K | 1 |
| Jia, D; Otsuki, M | 1 |
| Jia, D; Otani, M; Otsuki, M; Yamamoto, M | 1 |
| Akahane, S; Matsuzawa, A; Mori, Y; Oana, F; Tajima, N; Tokutate, Y | 1 |
| Brand, CL; Pickavance, LC; Wassermann, K; Wilding, JP | 1 |
| Akahane, S; Matsuzawa, A; Mori, Y; Oana, F; Tajima, N | 1 |
| Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Leor, J; Motro, M; Schwammenthal, E; Shemesh, J; Tanne, D; Tenenbaum, A | 1 |
| Perkins, JD | 1 |
| Miller, M | 1 |
| Boni, M; De Sio, G; Mazzanti, L; Monteburini, T; Polenta, M; Testa, I | 1 |
| de Ridder, JH; Jerling, JC; Kellerman, JA; Nel, CJ; Oosthuizen, W; Smuts, CM; van der Nest, DG; Veldman, FJ; Venter, CS; Vermaak, WJ; Vorster, HH | 1 |
3 review(s) available for bezafibrate and Obesity
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
[The Perspective of PPAR Dual/Pan Agonists as Therapeutic Drugs against NAFLD].
Topics: Bezafibrate; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Obesity; PPAR alpha | 2022 |
[Uncoupling protein-3 in skeletal muscle].
Topics: Animals; Bezafibrate; Carrier Proteins; Diabetes Mellitus; Energy Metabolism; Glucose; Humans; Hypolipidemic Agents; Insulin Resistance; Ion Channels; Lipid Metabolism; Mitochondrial Proteins; Muscle, Skeletal; Obesity; Uncoupling Protein 3 | 2002 |
1 trial(s) available for bezafibrate and Obesity
| Article | Year |
|---|---|
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Obesity; Prospective Studies; Treatment Outcome | 2005 |
18 other study(ies) available for bezafibrate and Obesity
| Article | Year |
|---|---|
Adverse association between obesity and menopause in mice treated with bezafibrate, a pan peroxisome proliferator-activated receptor agonist.
Topics: Adiposity; Animals; Bezafibrate; Diet, High-Fat; Female; Hypolipidemic Agents; Islets of Langerhans; Menopause; Mice; Mice, Inbred C57BL; Obesity; Ovariectomy; Peroxisome Proliferator-Activated Receptors | 2013 |
Peroxisome proliferator-activated receptors-alpha and gamma are targets to treat offspring from maternal diet-induced obesity in mice.
Topics: Adipocytes; Adipose Tissue, White; Animals; Bezafibrate; Body Weight; Carbohydrate Metabolism; Cell Size; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Energy Metabolism; Fatty Liver; Female; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR alpha; PPAR gamma; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Prenatal Nutritional Physiological Phenomena; Sterol Regulatory Element Binding Protein 1 | 2013 |
Long-chain free fatty acid profiling analysis by liquid chromatography-mass spectrometry in mouse treated with peroxisome proliferator-activated receptor α agonist.
Topics: Animals; Bezafibrate; Chromatography, Liquid; Fatty Acids, Nonesterified; Gene Expression; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Mass Spectrometry; Mice; Mice, Obese; Obesity; PPAR alpha; Stearoyl-CoA Desaturase | 2013 |
Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Fatty Liver; Glucose; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Peroxisome Proliferator-Activated Receptors | 2017 |
Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Energy Metabolism; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreatic Diseases; PPAR alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Weight Gain | 2009 |
Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Topics: Adipose Tissue; Animals; Bezafibrate; Diabetes Mellitus; Disease Models, Animal; Eating; Fatty Liver; Gene Expression Regulation; Glucose Tolerance Test; Glycosuria; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Metabolic Syndrome; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; RNA, Messenger; Sodium Glutamate | 2011 |
Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3.
Topics: Animals; Bezafibrate; Butyrates; Dietary Fats; Fibroblast Growth Factors; Gene Expression Regulation; HEK293 Cells; Hep G2 Cells; Histone Deacetylases; Humans; Hypolipidemic Agents; Liver; Male; Mice; Mice, Knockout; Mice, Obese; Obesity; PPAR alpha; Promoter Regions, Genetic; RNA, Messenger | 2012 |
AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
Topics: Alkanesulfonates; Animals; Bezafibrate; Carbohydrate Metabolism; Cinnamates; Diabetes Mellitus; Fatty Acids; Glucose; Humans; Insulin Resistance; Lipid Metabolism; Male; Mass Spectrometry; Mice; Mice, Obese; Molecular Structure; Obesity; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tumor Cells, Cultured | 2002 |
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Topics: Aging; Animals; Aromatase; Bezafibrate; Blood Glucose; Cholesterol; Estradiol; Glucose Tolerance Test; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Models, Animal; Obesity; Pioglitazone; Testosterone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats.
Topics: Actins; Animals; Bezafibrate; Blood Glucose; Cytokines; Diabetes Mellitus, Type 2; Hypolipidemic Agents; Insulin; Lipids; Obesity; Organ Size; Pancreas; Rats; Rats, Inbred OLETF; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2003 |
Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Eating; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Hypolipidemic Agents; Immunohistochemistry; Insulin; Insulin Resistance; Islets of Langerhans; Lipid Metabolism; Lipids; Obesity; Pancreas; Rats; Rats, Inbred OLETF; Triglycerides | 2004 |
Bezafibrate-induced changes over time in the expression of uncoupling protein (UCP) mRNA in the tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Carrier Proteins; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids; Gene Expression Regulation; Hypolipidemic Agents; Insulin; Ion Channels; Leptin; Male; Membrane Proteins; Membrane Transport Proteins; Mitochondrial Proteins; Obesity; PPAR alpha; PPAR delta; Rats; Rats, Inbred Strains; RNA, Messenger; Thyroid Hormones; Uncoupling Agents; Uncoupling Protein 1; Uncoupling Protein 2; Uncoupling Protein 3; Viscera | 2004 |
The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
Topics: Adipose Tissue; Animals; Bezafibrate; Body Composition; Body Weight; Diabetes Mellitus; Diet; Energy Metabolism; Glucose Clamp Technique; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Obesity; Organ Size; Oxazines; Pancreas; Phenylpropionates; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Receptors, Leptin; Thiazolidinediones | 2005 |
Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.
Topics: Adiponectin; Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Cholesterol, VLDL; Chylomicrons; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Hypolipidemic Agents; Intercellular Signaling Peptides and Proteins; Male; Obesity; Rats; Rats, Inbred OLETF; RNA, Messenger | 2004 |
Saying "Yes" to obese living liver donors: short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation.
Topics: Bezafibrate; Exercise Therapy; Fatty Liver; Humans; Hypolipidemic Agents; Liver Transplantation; Living Donors; Obesity | 2006 |
Bezafibrate reduces the incidence of type 2 diabetes mellitus in patients with obesity.
Topics: Aged; Bezafibrate; Body Mass Index; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypolipidemic Agents; Incidence; Middle Aged; Myocardial Infarction; Obesity; Time Factors; Triglycerides | 2006 |
[Treatment of hyperlipidemia in obese patients: monotherapy versus bi-therapy].
Topics: Adult; Bezafibrate; Cholesterol; Cholesterol, HDL; Drug Evaluation; Drug Therapy, Combination; Humans; Hyperlipidemias; Male; Middle Aged; Obesity; Pravastatin; Triglycerides | 1995 |
Soluble-fibre concentrate lowers plasminogen activator inhibitor-1 in baboons (Papio ursinus).
Topics: Analysis of Variance; Animals; Bezafibrate; Diet; Dietary Fiber; Glucose; Hypolipidemic Agents; Lipid Metabolism; Lipids; Lipoproteins; Liver; Male; Obesity; Papio; Plasminogen Activator Inhibitor 1; Random Allocation; Triglycerides | 1997 |